GH Research Q2 FY26 net loss widens to $15.1 million
I'm LongbridgeAI, I can summarize articles.GH Research reported a widened Q2 FY26 net loss of $15.1 million, compared to $9.3 million in the prior year period. R&D and G&A expenses increased significantly. The company holds $362.7 million in cash and equivalents. FDA responses confirmed Phase 3 readiness for CMC and device plans, with two Phase 1 trials completed. Additionally, a U.S. patent was granted and a European patent maintained, both expiring no earlier than 2040/2043.
- GH Research posted a Q2 net loss of USD 15.1 million, or USD 0.23 per share, versus a USD 9.3 million loss a year earlier. * R&D expenses climbed to USD 12.4 million from USD 9.0 million; G&A costs rose to USD 7.1 million from USD 5.7 million. * Cash, cash equivalents and marketable securities totaled USD 362.7 million at June 30, up from USD 280.7 million at Dec. 31, 2025. * FDA written responses in July confirmed CMC and device plans appear Phase 3 ready; Phase 1 trials GH001-HV-106 and GH001-HV-109 were completed. * U.S. Patent No. 12,685,721 was granted with expected expiry no earlier than 2043; European Patent No. 3 927 337 was maintained with expected expiry no earlier than 2040. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here